These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 8395104)

  • 1. Ganciclovir in cytomegalovirus prophylaxis in high-risk pediatric renal transplant recipients.
    Prokurat S; Drabik E; Grenda R; Vogt E
    Transplant Proc; 1993 Aug; 25(4):2577. PubMed ID: 8395104
    [No Abstract]   [Full Text] [Related]  

  • 2. Cytomegalovirus prophylaxis in pediatric renal transplant recipients.
    So S; Mayo C; McCullough C; Jendrisak M; Woodle S; Marsh W; Bailey T
    Transplant Proc; 1993 Feb; 25(1 Pt 2):1414-5. PubMed ID: 8382865
    [No Abstract]   [Full Text] [Related]  

  • 3. Cytomegalovirus infection in kidney transplantation: prophylaxis and management.
    Bulinski P; Toledo-Pereyra LH; Dalal S; Hernandez G
    Transplant Proc; 1996 Dec; 28(6):3310-1. PubMed ID: 8962286
    [No Abstract]   [Full Text] [Related]  

  • 4. [Effectiveness of preemptive therapy with ganciclovir in recipients of renal transplants at high risk (R-/D+) for the development of cytomegalovirus disease].
    Aranda-Verástegui F; Alberú J; Soto-Ramírez LE; González-Aguirre H; Muñoz Trejo T; Mancilla E; Díliz H; Correa-Rotter R; Sierra-Madero J
    Rev Invest Clin; 2002; 54(3):198-203. PubMed ID: 12183888
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preemptive therapy with gancyclovir for early high-risk CMV infection allows effective treatment with antithymocyte globulin of steroid-resistant rejection after renal transplantation.
    van Son WJ; van den Berg AP; The TH; Tegzess AM
    Transplant Proc; 1993 Feb; 25(1 Pt 2):1436-8. PubMed ID: 8382873
    [No Abstract]   [Full Text] [Related]  

  • 6. The problem of cytomegalovirus (CMV) prophylaxis in high-risk renal transplant recipients.
    Maiwald J; Sperschneider H; Stein G
    Nephrol Dial Transplant; 1996 Sep; 11(9):1897. PubMed ID: 8918658
    [No Abstract]   [Full Text] [Related]  

  • 7. Allograft rejection predicts the occurrence of late-onset cytomegalovirus (CMV) disease among CMV-mismatched solid organ transplant patients receiving prophylaxis with oral ganciclovir.
    Razonable RR; Rivero A; Rodriguez A; Wilson J; Daniels J; Jenkins G; Larson T; Hellinger WC; Spivey JR; Paya CV
    J Infect Dis; 2001 Dec; 184(11):1461-4. PubMed ID: 11709790
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ganciclovir prophylaxis to prevent CMV disease in kidney recipients undergoing anti-lymphocyte globulin treatment for acute rejection.
    Dickenmann MJ; Kabulbayev K; Steiger J; Cathomas G; Reusser P; Tamm M
    Clin Microbiol Infect; 2004 Apr; 10(4):337-9. PubMed ID: 15059125
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of oral ganciclovir in prevention of cytomegalovirus infection in post-kidney transplant patients.
    Ahsan N; Holman MJ; Yang HC
    Clin Transplant; 1997 Dec; 11(6):633-9. PubMed ID: 9408699
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Incidence of cytomegalovirus infection in kidney recipients.
    Bilgin N; Karakayali H; Moray G; Akkoç H; Turan M
    Transplant Proc; 1996 Aug; 28(4):2314-5. PubMed ID: 8769233
    [No Abstract]   [Full Text] [Related]  

  • 11. Cytomegalovirus prophylaxis with ganciclovir in kidney transplant recipients receiving induction antilymphocyte antibodies.
    Said T; Nampoory MR; Johny KV; Pacsa AS; Mini Abraham P; Nair MP; Abdel-Haleem M; Samhan M; Al-Mousawi M
    Transplant Proc; 2004; 36(6):1847-9. PubMed ID: 15350495
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ganciclovir prophylaxis delays but does not prevent cytomegalovirus infection in renal transplant recipients.
    Israni A; Krok K; Cohen D; Blumberg E; Bloom RD
    Transplant Proc; 2004 Dec; 36(10):3019-24. PubMed ID: 15686685
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of cytomegalovirus prophylaxis in renal retransplantation.
    Singh TP; Gruber SA; Lempert N; Freed B; Conti DJ
    Transplant Proc; 1995 Feb; 27(1):964-5. PubMed ID: 7879247
    [No Abstract]   [Full Text] [Related]  

  • 14. Cytomegalovirus infection in pediatric kidney transplantation.
    Fontana I; Verrina E; Timitilli A; Arcuri V; Basile G; Losurdo G; Rabagliati AM; Perfumo F; Giacchino R; Gusmano R
    Transplant Proc; 1994 Feb; 26(1):18-9. PubMed ID: 8108929
    [No Abstract]   [Full Text] [Related]  

  • 15. Cytomegalovirus: occurrence, severity, and effect on graft survival in simultaneous pancreas-kidney transplantation.
    Ricart MJ; Malaise J; Moreno A; Crespo M; Fernández-Cruz L;
    Nephrol Dial Transplant; 2005 May; 20 Suppl 2():ii25-ii32, ii62. PubMed ID: 15814546
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Early ganciclovir therapy effectively controls viremia and avoids the need for cytomegalovirus (CMV) prophylaxis in renal transplant patients with cytomegalovirus antigenemia.
    Gotti E; Suter F; Baruzzo S; Perani V; Moioli F; Remuzzi G
    Clin Transplant; 1996 Dec; 10(6 Pt 1):550-5. PubMed ID: 8996777
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevention of primary cytomegalovirus disease in organ transplant recipients with oral ganciclovir or oral acyclovir prophylaxis.
    Rubin RH; Kemmerly SA; Conti D; Doran M; Murray BM; Neylan JF; Pappas C; Pitts D; Avery R; Pavlakis M; Del Busto R; DeNofrio D; Blumberg EA; Schoenfeld DA; Donohue T; Fisher SA; Fishman JA
    Transpl Infect Dis; 2000 Sep; 2(3):112-7. PubMed ID: 11429021
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Follow-up of 28 HCMV seropositive renal-transplant recipients: comparison of clinical, biological and virological parameters in the groups of treated versus untreated infected patients.
    Kamar N; Mengelle C; Yahyaoui S; Sandres-Sauné K; Durand D; Izopet J; Rostaing L
    J Clin Virol; 2005 May; 33(1):35-42. PubMed ID: 15797363
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prospective study of the incidence, timing, significance, risk factors, and outcome of cytomegalovirus infection in liver transplant patients with double-drug immunosuppression and no prophylactic antiviral therapy.
    Sanchez-Turrión V; Cuervas-Mons V; Portero F; Barrios C; Garrido A; Albillos A
    Transplant Proc; 1993 Apr; 25(2):1786. PubMed ID: 8385824
    [No Abstract]   [Full Text] [Related]  

  • 20. Prophylactic immunoglobulin therapy improves the outcome of renal transplantation in recipients at risk for primary cytomegalovirus disease.
    Conti DJ; Freed BM; Lempert N
    Transplant Proc; 1993 Feb; 25(1 Pt 2):1421-2. PubMed ID: 8382867
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.